Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Upgrade Now
NasdaqCM - Delayed Quote USD

Allarity Therapeutics, Inc. (ALLR)

Compare
0.8836
-0.0265
(-2.91%)
At close: April 2 at 4:00:01 PM EDT
0.8798
-0.00
(-0.43%)
Pre-Market: 4:09:27 AM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for ALLR

Recent News: ALLR

View More
Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
GlobeNewswire 2 days ago
Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares

Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares
GlobeNewswire 9 days ago
Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology

Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology
GlobeNewswire 16 days ago
Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission

Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission
GlobeNewswire 20 days ago
Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration

Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration
GlobeNewswire 27 days ago
Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program

Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program
GlobeNewswire 30 days ago
Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit

Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit
GlobeNewswire last month
Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients

Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients
GlobeNewswire last month
Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer

Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer
GlobeNewswire last month
Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC

Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC
GlobeNewswire 2 months ago
Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements

Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements
GlobeNewswire 4 months ago
View More

Related Tickers

RNAZ TransCode Therapeutics, Inc.
0.5285
-2.29%
 
GNPX Genprex, Inc.
0.2950
+28.21%
 
DRMA Dermata Therapeutics, Inc.
0.9900
-0.97%
 
QNRX Quoin Pharmaceuticals, Ltd.
0.2925
+37.52%
 
CDT Conduit Pharmaceuticals Inc.
0.7469
+3.43%
 
HEPA Hepion Pharmaceuticals, Inc.
0.4780
-1.44%
 
SNSE Sensei Biotherapeutics, Inc.
0.3660
+5.84%
 
ONCO Onconetix, Inc.
0.0793
+4.76%
 
VRPX Virpax Pharmaceuticals, Inc.
1.2200
-4.69%
 
ADTX Aditxt, Inc.
5.0000
+10.62%